{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:43:28Z","timestamp":1782776608615,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Key Projects of Research and Development of China","award":["2016YFC0904600"],"award-info":[{"award-number":["2016YFC0904600"]}]},{"DOI":"10.13039\/501100001809","name":"the National\u2002Natural\u2002Science\u2002Foundation\u2002of\u2002China","doi-asserted-by":"crossref","award":["81972860"],"award-info":[{"award-number":["81972860"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Medical Scientific Research Foundation of Guangdong Province of China","award":["B2020065"],"award-info":[{"award-number":["B2020065"]}]},{"name":"the Capital Characteristic Clinic Project","award":["Z171100001017116"],"award-info":[{"award-number":["Z171100001017116"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The role of post-mastectomy radiotherapy (PMRT) in the treatment of patients with T1\u20132N1 breast cancer is controversial. This study\u2019s purpose was to evaluate the risk of recurrence of T1\u20132N1 breast cancer and the efficacy of PMRT in low-, medium- and high-risk groups of patients.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Post-mastectomy patients with T1\u20132N1 breast cancer were restaged according to the American Joint Committee on Cancer Staging Manual, 8th edition (AJCC 8th ed.) staging system. Recurrence scores were generated using prognostic factors identified for loco-regional recurrence and distant metastasis in patients without PMRT, and three risk groups were identified. Rates of loco-regional recurrence and distant metastasis were calculated with a competing risk model and compared using Gray\u2019s test. Disease-free survival and overall survival were calculated using the Kaplan-Meier method and compared using the log-rank test. The Cox proportional hazards regression model was used for the multivariate analysis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Data from 1986 patients (1521without PMRT; 465 with PMRT) were analyzed. Patients without PMRT were stratified into low-, intermediate- and high-risk groups by age, tumor location, AJCC 8th ed. stage, number of positive nodes and lympho-vascular invasion. The 5-year loco-regional recurrence rate and distant metastasis rates for the three risk groups were significant at 2.5, 5.4 and 16.2% (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009\u00a00.001) respectively, and 4.9, 8.4 and 18.6% (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009\u00a00.001) respectively. In the high-risk group, loco-regional recurrence (<jats:italic>p\u2009&lt;<\/jats:italic>\u2009\u00a00.001), and distant metastasis (<jats:italic>p<\/jats:italic>\u2009=\u20090.044) were significantly reduced, and disease free survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.004), and overall survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.029) were significantly improved after PMRT. In the low- and intermediate-risk groups, PMRT had no significant effect on loco-regional recurrence (<jats:italic>p<\/jats:italic>\u2009=\u20090.268), distant metastasis (<jats:italic>p<\/jats:italic>\u2009=\u20090.252), disease free survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.608) or overall survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.986).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our results showed no benefits of PMRT in the low-risk group, and thus, omitting PMRT radiotherapy in this population could be considered.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-07267-5","type":"journal-article","created":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T14:03:06Z","timestamp":1598277786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Effectiveness of the AJCC 8th edition staging system for selecting patients with T1\u20132N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986 patients from two institutions"],"prefix":"10.1186","volume":"20","author":[{"given":"Shulian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuran","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0985-235X","authenticated-orcid":false,"given":"Yexiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,24]]},"reference":[{"key":"7267_CR1","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","volume":"383","author":"P McGale","year":"2014","unstructured":"McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127\u201335.","journal-title":"Lancet"},{"key":"7267_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJM199710023371401","volume":"337","author":"M Overgaard","year":"1997","unstructured":"Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish breast Cancer cooperative group 82b trial. N Engl J Med. 1997;337:949\u201355.","journal-title":"N Engl J Med"},{"key":"7267_CR3","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S0140-6736(98)09201-0","volume":"353","author":"M Overgaard","year":"1999","unstructured":"Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish breast Cancer cooperative group DBCG 82c randomised trial. Lancet. 1999;353:1641\u20138.","journal-title":"Lancet"},{"key":"7267_CR4","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1056\/NEJM199710023371402","volume":"337","author":"J Ragaz","year":"1997","unstructured":"Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337:956\u201362.","journal-title":"N Engl J Med"},{"key":"7267_CR5","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1016\/j.ijrobp.2012.01.076","volume":"83","author":"RD Tendulkar","year":"2012","unstructured":"Tendulkar RD, Rehman S, Shukla ME, et al. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy. Int J Radiat Oncol Biol Phys. 2012;83:e577\u201381.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7267_CR6","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.3747\/co.20.1540","volume":"20","author":"C Lu","year":"2013","unstructured":"Lu C, Xu H, Chen X, et al. Irradiation after surgery for breast cancer patients with primary tumours and one to three positive axillary lymph nodes: yes or no? Curr Oncol. 2013;20:e585\u201392.","journal-title":"Curr Oncol"},{"key":"7267_CR7","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ijrobp.2014.02.013","volume":"89","author":"A McBride","year":"2014","unstructured":"McBride A, Allen P, Woodward W, et al. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014;89:392\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7267_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clon.2007.10.004","volume":"20","author":"IH Kunkler","year":"2008","unstructured":"Kunkler IH, Canney P, van Tienhoven G, Russell NS. Elucidating the role of chest wall irradiation in 'intermediate-risk' breast cancer: the MRC\/EORTC SUPREMO trial. Clin Oncol (R Coll Radiol). 2008;20:31\u20134.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"7267_CR9","doi-asserted-by":"crossref","unstructured":"Weiss A, Chavez-MacGregor M, Lichtensztajn DY, et al. Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer. JAMA Oncol. 2017.","DOI":"10.1001\/jamaoncol.2017.4298"},{"key":"7267_CR10","unstructured":"AJCC Cancer Staging Manual Eighth Edition. 2017 22-Nov-2017 [cited; Available from: https:\/\/cancerstaging.org\/About\/news\/Pages\/Updated-Breast-Chapter-for-8th-Edition.aspx."},{"key":"7267_CR11","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/annonc\/mdv106","volume":"26","author":"S Gourgou-Bourgade","year":"2015","unstructured":"Gourgou-Bourgade S, Cameron D, Poortmans P, et al. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (definition for the assessment of time-to-event endpoints in CANcer trials)dagger. Ann Oncol. 2015;26:873\u20139.","journal-title":"Ann Oncol"},{"key":"7267_CR12","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1245\/s10434-016-5435-5","volume":"23","author":"SF Lai","year":"2016","unstructured":"Lai SF, Chen YH, Kuo WH, et al. Locoregional recurrence risk for Postmastectomy breast Cancer patients with T1-2 and one to three positive lymph nodes receiving modern systemic treatment without radiotherapy. Ann Surg Oncol. 2016;23:3860\u20139.","journal-title":"Ann Surg Oncol"},{"key":"7267_CR13","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1245\/s10434-014-4321-2","volume":"22","author":"RM Lanning","year":"2015","unstructured":"Lanning RM, Morrow M, Riaz N, et al. The effect of adjuvant Trastuzumab on Locoregional recurrence of human epidermal growth factor receptor 2-positive breast Cancer treated with mastectomy. Ann Surg Oncol. 2015;22:2517\u201325.","journal-title":"Ann Surg Oncol"},{"key":"7267_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1200\/JCO.2005.12.044","volume":"23","author":"CI Sartor","year":"2005","unstructured":"Sartor CI, Peterson BL, Woolf S, et al. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344. J Clin Oncol. 2005;23:30\u201340.","journal-title":"J Clin Oncol"},{"key":"7267_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.radonc.2013.08.020","volume":"108","author":"M van Hezewijk","year":"2013","unstructured":"van Hezewijk M, Bastiaannet E, Putter H, et al. Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane adjuvant multinational (TEAM) trial. Radiother Oncol. 2013;108:190\u20136.","journal-title":"Radiother Oncol"},{"key":"7267_CR16","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/jso.24071","volume":"112","author":"K Yao","year":"2015","unstructured":"Yao K, Liederbach E, Lutfi W, et al. Increased utilization of postmastectomy radiotherapy in the United States from 2003 to 2011 in patients with one to three tumor positive nodes. J Surg Oncol. 2015;112:809\u201314.","journal-title":"J Surg Oncol"},{"key":"7267_CR17","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.ijrobp.2004.08.009","volume":"61","author":"PT Truong","year":"2005","unstructured":"Truong PT, Olivotto IA, Kader HA, et al. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:1337\u201347.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7267_CR18","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1245\/s10434-013-3117-0","volume":"20","author":"TA Moo","year":"2013","unstructured":"Moo TA, McMillan R, Lee M, et al. Selection criteria for postmastectomy radiotherapy in t1-t2 tumors with 1 to 3 positive lymph nodes. Ann Surg Oncol. 2013;20:3169\u201374.","journal-title":"Ann Surg Oncol"},{"key":"7267_CR19","doi-asserted-by":"crossref","unstructured":"Park HJ, Shin KH, Kim JH, et al. Incorporating risk factors to identify the indication of post-mastectomy radiotherapy in N1 breast Cancer treated with optimal systemic therapy: a multicenter analysis in Korea (KROG 14-23). Cancer Res Treat. 2016.","DOI":"10.4143\/crt.2016.405"},{"key":"7267_CR20","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2007.14.5565","volume":"26","author":"M Kyndi","year":"2008","unstructured":"Kyndi M, Sorensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish breast Cancer cooperative group. J Clin Oncol. 2008;26:1419\u201326.","journal-title":"J Clin Oncol"},{"key":"7267_CR21","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1245\/s10434-017-6009-x","volume":"24","author":"EA Mittendorf","year":"2017","unstructured":"Mittendorf EA, Chavez-MacGregor M, Vila J, et al. Bioscore: a staging system for breast Cancer patients that reflects the prognostic significance of underlying tumor biology. Ann Surg Oncol. 2017;24:3502\u20139.","journal-title":"Ann Surg Oncol"},{"key":"7267_CR22","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","volume":"366","author":"M Clarke","year":"2005","unstructured":"Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087\u2013106.","journal-title":"Lancet"},{"key":"7267_CR23","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMra065241","volume":"356","author":"RS Punglia","year":"2007","unstructured":"Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. N Engl J Med. 2007;356:2399\u2013405.","journal-title":"N Engl J Med"},{"key":"7267_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1415369","volume":"373","author":"PM Poortmans","year":"2015","unstructured":"Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast Cancer. N Engl J Med. 2015;373:317\u201327.","journal-title":"N Engl J Med"},{"key":"7267_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1415340","volume":"373","author":"TJ Whelan","year":"2015","unstructured":"Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast Cancer. N Engl J Med. 2015;373:307\u201316.","journal-title":"N Engl J Med"},{"key":"7267_CR26","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1200\/JCO.2015.63.6456","volume":"34","author":"LB Thorsen","year":"2016","unstructured":"Thorsen LB, Offersen BV, Dano H, et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast Cancer. J Clin Oncol. 2016;34:314\u201320.","journal-title":"J Clin Oncol"},{"key":"7267_CR27","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","volume":"30","author":"HJ Burstein","year":"2019","unstructured":"Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen international consensus guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30:1541\u201357.","journal-title":"Ann Oncol"},{"key":"7267_CR28","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1245\/s10434-018-6565-8","volume":"25","author":"JG Bazan","year":"2018","unstructured":"Bazan JG, Majithia L, Quick AM, et al. Heterogeneity in outcomes of pathologic T1-2N1 breast Cancer after mastectomy: looking beyond Locoregional failure rates. Ann Surg Oncol. 2018;25:2288\u201395.","journal-title":"Ann Surg Oncol"},{"key":"7267_CR29","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S0360-3016(02)02850-X","volume":"53","author":"TA Buchholz","year":"2002","unstructured":"Buchholz TA, Katz A, Strom EA, et al. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2002;53:880\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7267_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1245\/s10434-016-5558-8","volume":"24","author":"A Recht","year":"2017","unstructured":"Recht A, Comen EA, Fine RE, et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update. Ann Surg Oncol. 2017;24:38\u201351.","journal-title":"Ann Surg Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07267-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07267-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07267-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T23:26:23Z","timestamp":1629761183000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07267-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,24]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7267"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07267-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,24]]},"assertion":[{"value":"3 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Institutional Review Board of the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (approval number 15\u2013057\/984). Due to the retrospective nature of this study, the informed consent requirement was waived.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"792"}}